Trials / Unknown
UnknownNCT05467254
Evaluate the Safety and Efficacy of CLL1+CD33 CAR-T in Patients With R/R AML
To Evaluate the Safety and Efficacy of CLL1+CD33 CAR-T in Patients With Relapsed and Refractory Acute Myeloid Leukemia
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Zhejiang University · Academic / Other
- Sex
- All
- Age
- 2 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This is an open label, phase I study to assess the safety and efficacy of CLL1+CD33 CAR-T in patients with relapsed and refractory acute myeloid leukemia
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CLL1+CD33 CAR-T | CLL1+CD33 CAR-T is a new type CAR-T cells therapy for patients with acute myeloid leukemia. |
Timeline
- Start date
- 2022-08-02
- Primary completion
- 2024-08-02
- Completion
- 2025-08-02
- First posted
- 2022-07-20
- Last updated
- 2022-07-20
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05467254. Inclusion in this directory is not an endorsement.